JPRN-jRCT2080221031UnknownPhase 2
A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Adult Subjects
ovartis Pharma K.K.0 sites200 target enrollmentStarted: March 2, 2010Last updated:
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- >= 20age old to <= 60age old (—)
- Sex
- All
Inclusion Criteria
- •Healthy Japanese adults aged 20 to 60 years
Exclusion Criteria
- •- History of anaphylaxis, serious vaccine reactions, hypersensitivity to vaccine viral proteins or excipients
- •- Administration of adjuvanted influenza vaccine or suspected influenza disease within 3 month prior to study start
- •- Administration of any other vaccines within 4 weeks prior to enrollment expect for seasonal influenza vaccines within 1 week
- •- History of progressive or severe neurological disorders
Investigators
Similar Trials
Unknown
Phase 2
A Multi-center, Randomized, Single-blind, Dose-Ranging Study to Evaluate Immunogenicity, Safety and Tolerability of Different Doses of Adjuvanted Cell-Derived, Inactivated Novel Swine Origin A/H1N1 Monovalent Subunit Influenza Virus Vaccine in Healthy Japanese Pediatric SubjectsJPRN-jRCT2080221032ovartis Pharma K.K.120
Active, not recruiting
Not Applicable
Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric SubjectsEUCTR2014-005075-88-Outside-EU/EEAovartis Pharma K.K120
Active, not recruiting
Phase 1
A Multi-Center, Double-Blind, Randomized, Dose-Ranging Study of the Safety and Efficacy of IDP-102 Gel 5 %, and 15 % Compared with Vehicle in the Treatment of Common Warts.common wartsEUCTR2005-002820-32-DEDow Pharmaceutical Sciences Inc.107
Active, not recruiting
Not Applicable
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys and Copegus versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection. - NDChronic Hepatitis C (CHC) Genotype 1 or 4MedDRA version: 12.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-008258-21-ITF. Hoffmann - La Roche Ltd - Pharmaceutical Division, PDR400
Active, not recruiting
Phase 1
A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection.EUCTR2008-008258-21-GBF. Hoffmann-La Roche Ltd400